Colorectal Cancer Therapeutics Market is estimated to be US$ 16.36 billion by 2030 with a CAGR of 5.3% during the forecast period

[Amar Yadav]

Colorectal cancer, also known as bowel cancer, colon or rectal cancer, is the development of tumor in the parts of large intestine. Signs and symptoms may include blood in the stool, a change in bowel movement, weight loss, and fatigue. Many cases of colon cancer have no signs but if there is symptom one may feel abdominal pain and tenderness in the lower abdomen. Once it is started developing in colon, its progression will change according the cellular growth of the tumor and other factors, such as age and health conditions of patient. In general, its progression rate is very slow, but still, it is serious disease. The increasing prevalence of colorectal cancer globally which is the key factor driving the growth of colorectal cancer therapeutics market. This is because of increasing cases, demand of advance therapeutics etc. are boosting the demand of such treatments. Thus, increasing research on such cancers and development of various drugs in laboratories are expected to propel the growth of this particular market.

Region Analysis:
In the colorectal cancer therapeutics market, North America is currently dominating the market. Due to rising geriatric population, advanced technologies, highest investment in pharmaceuticals and R&D department etc. which are driving the market in this region.

Key Development:
• In 2022, Memorial Sloan Kettering Cancer Center performed a clinical trials of new drug Dostarlimab on 18 patients for the period of six months, and for the first time in the history all of them had their cancer vanished.
• In 2021, Bristol Myers Squibb announced the approval of opdivo plus Yervoy from the European Commission to treat adult patient with microsatellite instability-high (MSI-H) metastatic colorectal cancer.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/reque...
Segmentation:
The Global Colorectal Cancer Therapeutics Market accounted for US$ 9.8 billion in 2020 and is estimated to be US$ 16.36 billion by 2030 and is anticipated to register a CAGR of 5.3%. The Global Colorectal Cancer Therapeutics Market is segmented by Type, Drug Class, Sales Channel, Top-Selling Drugs, and Region.
• By type, the Global Colorectal Cancer Therapeutics Market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others.
• By drug class, the Global Colorectal Cancer Therapeutics Market is classified into Immunotherapy, Chemotherapy, and Targeted Therapy.
• By sales channel, the Global Colorectal Cancer Therapeutics Market is classified into Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.
• By top selling drugs, the Global Colorectal Cancer Therapeutics Market is classified into 5-Flurorouracil, Capecitabine, Irinotecan, Oxaliplatin, and Trifluridine & Tipiracil.

Competitive Analysis:
The key players operating in the global colorectal cancer therapeutics market includes Pfizer Inc., Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Inc., Biocon Ltd.

OTHER RELATED REPORTS:-
https://chaitanyahcblogs.blogspot.com/2022/06/new-drug-dostarlimab-...

https://www.reddit.com/r/unitedstatesofindia/comments/v7nrkx/new_dr...

https://sites.google.com/view/dostarlimab/home